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The prevalence of overweight and obesity is increasing in children and adolescents worldwide raising the question on the approach
to this condition because of the potential morbidity, mortality, and economic tolls. Dietetic and behavioral treatments alone have
only limited success; consequently, discussion on strategies for treating childhood and adolescent obesity has been promoted.
Considering that our knowledge on the physiological systems regulating food intake and body weight is considerably increased,
many studies have underlined the scientific and clinical relevance of potential treatments based on management of peripheral
or central neuropeptides signals by drugs. In this paper we analyze the data on the currently approved obesity pharmacological
treatment suggesting the new potential drugs.
1. Introduction
The report from the International Obesity Taskforce (IOTF)
on worldwide prevalence rate shows that the pediatric obe-
sity epidemic has spread globally. The worldwide prevalence
of overweight in children and adolescents is approximately
10% with many western countries approaching 30%. In fact,
some countries in economic transition have also prevalence
rate increase higher than those in the United States (US) [1–
3].
Because of the number of the subjects, obesity is now
recognized as a healthcare issue on an epidemic scale in
both adult and pediatric populations, but it yet remains an
unsolved medical problem [4].
The successful management of obesity is theoretically
possible through lifestyle changes including diet modifi-
cations [5] and increased physical activity. The literature
analysis demonstrated, however, that significant results were
obtained only in a limited number of subjects and for
a relatively short time period: also the management with
psychological involvement let the problem substantially
unsolved. These considerations recently promoted an inter-
est in pharmacological interventions and bariatric surgery
[4].
The renewed interest for a pharmacological approach
depends on the knowledge of physiological systems involved
in the control of food intake and body weight that has
considerably increased over the past decade. A powerful
and complex physiological system, based on both aﬀerent
and eﬀerent signals, regulating food intake and energy
homeostasis, has been elucidated. This system consists of
multiple pathways with redundancy signals that are trans-
mitted by both blood and peripheral nerves, which are
integrated in brain centres with subsequent regulation of
central neuropeptides which in turn modulate feeding and
energy expenditure. Appetite includes diﬀerent aspects of
eating patterns, such as frequency and size of eating, choice of
high-fat or low-fat foods, energy density of consumed foods,
variety of accepted foods, palatability of diet, and variability
in day-to-day intake. Feeding behavior is controlled by a
series of short-term hormonal, psychological, and neural
signals. All signals act at several central nervous system
(CNS) sites, but the pathways converge on the hypothalamus,
a central region of feeding regulation, containing numerous
peptides and neurotransmitters that influence food intake
[6]. CNS also regulates energy homeostasis on the basis of
peripheral signals from the gastrointestinal tract (GIT) and
adipose tissue.
2 Journal of Obesity
Table 1: Neurotransmitters influencing appetite.
Neurotransmitters that
increase food intake
Neurotransmitters that decrease
food intake
Agouti-related peptide
Alpha melanocyte-stimulating
hormone
Neuropeptide Y
Bombesin-/gastrin-releasing
peptide
Melanin-concentrating
hormone
Calcitonin gene-related peptide
Orexin Cholecystokinin
Galanin Corticotrophin-releasing factor
Ghrelin Dopamine
Nitric oxide GABA
Noradrenaline Glucagon
Opioids (particularly μ and κ
agonists)
Glucagon-like peptide 1 (7–36)
amide
Neurotensin
Serotonin
In this paper, we summarize the currently approved
pharmacological treatment for children and adolescents, and
we are going to provide an overview of developing drugs.
2. Pharmacological Treatment of Obesity
Current and putative antiobesity drugs share the same
fundamental principles as treatment in adults, that is, to
decrease caloric intake and increase energy expenditure,
miming the eﬀects of some anorectic neuropeptides or
contrasting the orectic ones in order to regulate energy
balance (Tables 1 and 2).
However, the primary goal of overweight/obesity treat-
ment (i.e., weight reduction or deceleration of weight gain)
and the recommended way of intervention are variable
and dependent on the child’s age and level of overweight,
among other considerations. In order to support clinicians
in determining the most appropriate form of treatment,
pediatric weight management guidelines exist in many
countries to promote best practice, but at present many of
these recommendations are based on low-grade scientific
evidence.
A recent guideline suggests considering pharmacother-
apy in
(1) obese children only after failure of a formal program
of intensive lifestyle modification;
(2) overweight children only if severe comorbidities
persist despite intensive lifestyle modification, par-
ticularly in children with a strong family history
for type 2 diabetes or premature cardiovascular
disease. Pharmacotherapy should be provided only
by clinicians who are experienced in the use of anti-
obesity agents and aware of the potential for adverse
reactions [7].
Up to now, only three drugs have been reported to
reduce weight and/or body mass index (BMI) in adolescents:
(1) sibutramine, a neurotransmitter reuptake inhibitor which
enhances satiety by inhibiting the reuptake of serotonin,
norepinephrine, and dopamine, (2) orlistat, a pancreatic
lipase inhibitor which reduces fat absorption, and (3) met-
formin, an antihyperglycemic and insulin-sensitizing agent
(Table 3).
At present, there are only few drugs approved by the
Food and Drug Administration (FDA) for the treatment of
adult obesity. The most important ones are sibutramine and
orlistat. The FDA in the US approved the latter drug in 2003,
and it has recently been approved by the European Union for
the treatment of adolescents.
3. Current Available Drugs
3.1. Drugs Aﬀecting Peripheral Mechanisms
3.1.1. Orlistat. Orlistat, approved since 1998, is an inhibitor
of pancreatic lipase reducing dietary fat absorption. The
compound is a partially hydrated derivative of an endoge-
nous lipstatin produced by Streptomyces toxytricini [19].
Orlistat binds irreversibly to the active sites of lipase
through covalent binding. Approximately one-third of
triglyceride intakes does not undergo digestion and is not
absorbed by small intestine, crossing the GI tract and being
eliminated. Because of low systemic absorption and first-pass
metabolism, the bioavailability of orlistat is <1%; most of the
drug being excreted remains unchanged with stools [20].
In adults, orlistat has a good safety profile, is gener-
ally well tolerated, has minimal systemic absorption, and
determines clinically meaningful and sustained decreases in
weight and BMI when combined with a mildly hypocaloric
diet and exercise. It is approved for weight management in
overweight and obese adults in more than 120 countries,
and to date more than 22 million patients have received this
drug. Based on clinical and safety characteristics in adult
populations, it was considered a logical choice for study in
the obese pediatric population because of the nonsystemic
mechanism of action.
FDA in December 2003 approved orlistat use in adoles-
cents aged 12 to 18 years old with a BMI (kg/m2) > 2 units
above the reference value at the 95th percentile for age and
gender. This conclusion was based on the results of a one-
year study evaluating 539 American adolescents submitted to
a hypo-caloric diet plus exercise and behavioral therapy and
that were randomized to orlistat versus placebo: a significant
decrease in BMI was shown in the orlistat group (0.55
versus 0.31 kg/m2 for placebo; P < .01) [8]. Moreover, body
composition analysis showed that orlistat did not aﬀect the
normal increase in lean body mass physiologically observed
in adolescents, and the weight diﬀerence between the placebo
and orlistat groups was due to a diﬀerence in fat mass. The
use of orlistat for 1 year in this adolescent population did
not raise major safety issues although GIT adverse events,
such as fatty or oily stools, oily spotting, increased defecation,
cramps, and abdominal pain, were more common in the
orlistat group.
Chanoine et al. also measured estradiol levels, cardio-
vascular eﬀects, gallbladder structure, renal structure, bone
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Table 2: Selected GI, pancreatic, and adipose tissue peptides that regulate food intake.
Peptide Main site of synthesis Receptors mediating feeding eﬀects Eﬀect on food intake
CCK Proximal intestinal I cells CCK1R inhibition
GLP-1 Distal intestinal L cells GLP-1R inhibition
Oxyntomodulin Distal intestinal L cells GLP-1R and others inhibition
PYY Distal intestinal L cells Y2R inhibition
Enterostatin Exocrine pancreas F1-ATPase beta subunit inhibition
APO AIV Intestinal epithelial cells Unknown inhibition
PP Pancreatic F cells Y4R, Y5R inhibition
Amylin Pancreatic beta cells CTRS, RAMPS inhibition
GRP and NMB Gastric myenteric neurons GRPR inhibition
Gastric leptin Gastric chief and P cells Leptin receptor inhibition
Ghrelin Gastric x/a-like cells Ghrelin receptor stimulation
Insulin Pancreatic beta cells Insulin receptor inhibition
Leptin Adipocytes Leptin receptor inhibition
Adiponectin Adipocytes Adiponectin receptor inhibition
CTRs: calcitonin receptors; RAMPs: receptor activity-modifying proteins; GRP: gastrin-releasing peptide; NMB: neuromedin B; GRPR: GRP receptor.
mineral content/density, and other non-GIT adverse events
[8]. Girls in the orlistat group had a statistically significant
decrease in estradiol concentrations compared with a slight
increase shown in the placebo intervention. Ten participants
in the orlistat group and one participant in the placebo
group developed abnormalities during the study that were
detected on electrocardiograms; none of these was believed
to be related to the medication based on review by an
independent cardiologist. No other adverse cardiovascular
eﬀects were found. At the end of the study, six participants in
the orlistat intervention (compared with one participant in
the placebo intervention) were found to have asymptomatic
gallstones not seen at baseline; five of these patients had lost
large amounts of weight (8.2–29.4 kg), and two were siblings.
Another patient had multiple gallstones on ultrasound at
day 167 after a 15.8 kg weight loss and had a subsequent
cholecystectomy. Ultrasound also identified two additional
new renal abnormalities in the orlistat intervention group
(mild left hydronephrosis and 6mm echogenic focus without
evidence of renal calculus). There were no diﬀerences in bone
mineral content/density between the two interventions.
Most other non-GIT adverse events were also more
prevalent in the orlistat group compared with the placebo
group, but the diﬀerence between groups was less pro-
nounced than for GIT adverse events; the most common
adverse events in this category were headache, upper respi-
ratory tract infection, and nasopharyngitis [8].
As in adults, 120mg three times daily prescribed with
meals are usually necessary to produce a significant eﬀect.
Coprescription of a daily multivitamin (A, D, E, and K) is
recommended to prevent possible deficiencies of fat-soluble
vitamins, due to the interferences with the absorption of
them.
Orlistat should be avoided in patients with chronic
diarrhea [4, 20, 21]. Moreover, it can reduce the absorption
of amiodarone [22], and ciclosporin [23] and can increase
warfarin’s action [20, 24]. Systemic adverse eﬀects are
minimal because of the lack of systemic absorption.
3.1.2. Metformin. Metformin is an eﬀective oral hypo-
glycemic agent used in the treatment of adults with type 2
diabetes and other conditions with insulin resistance [25–
27]. Its hypoglycemic eﬀect is largely caused by inhibition of
hepatic gluconeogenesis, increased insulin-mediated glucose
disposal, and inhibition of fatty acid oxidation. Reduction
of intestinal glucose absorption has been hypothesized as
another possible mechanism of action, although data have
been inconsistent [28]. The exact mechanism of intracellular
action of metformin remains uncertain. Metformin is poorly
metabolized, and 90% of the absorbed drug is eliminated as
unchanged in urine. Plasma protein binding is insignificant,
so the drug is dialyzable.
Metformin therapy for insulin resistance and obesity is
safe and well tolerated and has a beneficial eﬀect on weight,
BMI, waist circumference, abdominal fat, fasting insulin, and
fasting glucose although 6 months of therapy may not be
suﬃcient to have an eﬀect on visceral adipose tissue loss and
insulin sensitivity [29]. Metformin is currently being used in
more than 90 countries worldwide.
According to recent studies, the major eﬀect of met-
formin may be a powerful inhibition of appetite under the
light of the well-known role of weight excess on hyperten-
sion, type 2 diabetes, and dyslipidemia [30]. Because the
major component of metabolic syndrome is weight excess,
by contrasting it, this drug can also be able to prevent most
of its consequences on health.
The potential clinical application of metformin in the
pediatric population was first described in the 1970s in a
small published study demonstrating the beneficial eﬀect on
weight and insulin concentrations in 8–14-year-old obese
children [31]. Subsequent pediatric randomized, controlled
trial studies have shown improvement in BMI, fasting serum
glucose, insulin, and lipid profile in patients on metformin
therapy for exogenous obesity associated with insulin resis-
tance [9–11]. Participants received metformin for 6 months
at a daily dose of 1 g (0.5 g twice daily) [11] or 2 g (1 g
twice daily) [9]. There were no withdrawals due to adverse
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Table 3: Summary of studies about orlistat, metformin, and sibutramine in children and adolescents.
Authors and
year
Drug
Population
treated
Age
(years)
Duration
Eﬀects on BMI or other
metabolic eﬀects
Adverse events
Chanoine et
al. 2005 [8]
Orlistat
357 obese
adolescent
12–16 1 year BMI: −0.55 SD
Mild to moderate
gastrointestinal tract
adverse events
(9%–50%)
Srinivasan et
al. 2006 [9]
Metformin 28 9–18 6 months
BMI: −1.26 Kg/m2
(P = .002); waist
circumference: −2.8 cm
(P = .003); fasting insulin:
−2.2mU/liter (P = .011)
Nausea
Kay et al.
2001 [10]
Metformin 24 15.6 ± 0.4 8 weeks
Body fat: −6.0 ± 0.62;
fat-free mass was similar in
metformin group and
placebo. Enhances insulin
sensitivity, significant
reduction in plasma leptin,
cholesterol, triglycerides,
and free fatty acid.
Nausea, dizziness, and
stools
Freemark and
Bursey 2001
[11]
Metformin 29 12–19 6 months
BMI: decline of 0.12 SD and
a 5.5% reduction in serum
leptin in girls. Metformin
caused a progressive decline
in fasting blood glucose
and a reduction in fasting
insulin levels.
Transient abdominal
discomfort or diarrhea
Jones et al.
2002 [12]
Metformin 82 10–16 16 weeks
Improved glycemic control,
the adjusted mean change
from baseline in fasting
plasma glucose was
−2.4mmol/L. Mean HbA1c
values was significantly
lower.
Gastrointestinal side
eﬀects (diarrhea)
Berkowitz et
al. 2003 [13]
Sibutramine 82 13–17 6 months BMI: −8.5%
Elevated blood pressure
and/or pulse rate,
ventricular premature
beats, cholelithiasis,
ecchymoses, and rash
Berkowitz et
al. 2006 [14]
Sibutramine 498 12–16 12 months
BMI: −2.9 Kg/m2; body
weight: −8.4 Kg (P < .001
for both); greater
improvements in
triglyceride levels,
high-density lipoprotein
cholesterol levels, insulin
levels and sensitivity
Tachycardia
Garcia-
Morales et al.
2006 [15]
Sibutramine 46 14–18 6 months BMI: −9.2%
No significant diﬀerence
in blood pressure,
tachycardia, headache
with nausea, or weakness
Godoy-Matos
et al. 2005
[16]
Sibutramine 60 14–17 6 months
The mean BMI reduction
was greater in the
sibutramine group: 3.6 ±
2.5 Kg/m2
No significant diﬀerence
in blood pressure or
heart rate
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Table 3: Continued.
Authors and
year
Drug
Population
treated
Age
(years)
Duration
Eﬀects on BMI or other
metabolic eﬀects
Adverse events
Van Mil et al.
2007 [17]
Sibutramine 24 12–17 12 weeks
Eﬀect on BMI-SDS not
significant
Abdominal complaints,
insomnia, headache, loss
of interest, and loss of
appetite
Daniels et al.
2007 [18]
Sibutramine 498 12–16 12 months
BMI reduction was > or =
5%
Small mean decreases in
blood pressure and pulse
rate were seen in both
sibutramine and placebo
events in either of the study; however, medication dose was
lowered due to nausea in three participants (Freemark (2001)
n = 1; Srinivasan (2006) n = 2). In both studies, there
was no adverse eﬀect on serum lactate, measures of liver,
or renal function. Freemark et al. reported that there were
no episodes of vomiting or lactic acidosis. Srinivasan et al.,
demonstrated that there was no biochemical evidence of
metformin toxicity. In one study, three metformin-treated
patients and one placebo patient complained of transient
abdominal discomfort or diarrhea that resolved within the
first one to two weeks of therapy, and another participant
may have had an exacerbation of migraine [11].
Metformin treatment has been approved in children
older than 10 years. The beneficial role of this drug in young
patients with type 2 diabetes has been demonstrated in a
randomized, controlled trial [12].
3.2. Drugs Aﬀecting Central Mechanisms
3.2.1. Serotonin and Noradrenaline Reuptake Inhibitors
(SNRIs). Anorectic medications targeting the 5-HT system
are typically derived from beta-phenethylamine and mediate
their eﬀects by influencing noradrenergic, dopaminergic,
and serotonergic neurotransmission [4].
Sibutramine. Sibutramine was originally developed as an
antidepressant, and it is a centrally acting monoamine
reuptake inhibitor that mainly acts to increase satiety [32].
Its most important mechanism of action is to block nor-
epinephrine and 5-HT re-uptake, but it also stimulates ther-
mogenesis that plays a minor role in weight reduction [33].
Sibutramine undergoes extensive first-pass metabolism,
mainly by hepatic cytochrome p450 3A4 enzymes, toactivate
primary and secondary amine metabolites that are more
potent than the parent compound. The drug and its active
metabolites are mainly excreted through the kidney [20].
Sibutramine was approved for adults in the US in 1997
and in the European Union in 1999. Consumer advocacy
group Public Citizen campaigned to have sibutramine with-
drawn from the market in the US, and two deaths in Italy
led to an international investigation in 2002 and temporary
removal from the market. In the US, sibutramine may be
used in adolescents older than 16 years [34].
The addition of sibutramine to a behavior therapy
program resulted in statistically significant improvements in
BMI [13–17]. Berkowitz et al. reported that 7–12 months
of sibutramine treatment decreased BMI by 2.4%, respect to
placebo [13]. In an RCT including 498 adolescents the same
authors also showed a reduction of BMI and body weight,
and an improvement of metabolic profile in the sibutramine-
treated group [14].
Godoy-Matos et al. studied 60 Brazilian adolescents and
documented that approximately 25% of adolescents assigned
to the sibutramine group reduced their initial weight by at
least 15% in comparison to 0% in the placebo group (P <
.001) [16].
A common landmark is that the eﬃcacy of sibutramine
is greatly enhanced when used with intensive lifestyle
modification and behavior therapy [13–17].
The most common adverse eﬀects found in adolescents
taking sibutramine was tachycardia, even if generally it was
not a reason to withdraw from treatment [13–16]. Other
common side eﬀects include insomnia, elevation of blood
pressure, headache, dizziness, dry mouth, and constipation.
Long-term data on the eﬀect of sibutramine on major
obesity-related morbidity are lacking. However, the ongoing
Sibutramine Cardiovascular Outcomes trial (SCOUT) is
assessing the eﬃcacy of sibutramine in reducing myocardial
infarction, stroke, and cardiovascularmortality in 9000 obese
and overweight patients [35]. It is important to notice that
sibutramine eﬀects on heart rate and blood pressure in
obese adolescents are generally neutralized by the eﬀective
reduction in BMI that seems to be even better than that
observed in adults [18].
Phentermine. Phentermines’ use is only approved for short-
term treatment of obesity in adults of up to 3 months
duration due to the lack of long-term studies [36].
It has been demonstrated that, in subjects treated
with phentermine, the weight loss was greater (from 2 to
10 kg) than in those receiving placebo. Patients treated with
phentermine at the dosage from 15mg/d to 30mg/d lost
an average of 3.6 kg (95% CI, 0.6 to 6 kg) of additional
weight compared with placebo (the duration of treatment
with phentermine varied from 2 to 24 weeks). The authors
concluded that treatment with phentermine, in addition to
lifestyle interventions, resulted in a statistically significant
but modest increase in weight loss. In 1961–1963 Lorber car-
ried out a trial including 84 children aged from 3 to 13 years
to evaluate the eﬀects of this new drug compared to placebo.
Only 68 subjects completed the entire course of 12 weeks,
divided into three period, of 4 weeks, during which three
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diﬀerent types of treatment were prescribed (amphetamine
resinate, phentermine, and diet with placebo). Authors
concluded that phentermine was somewhat more eﬃcient
than both diet or the lower dose of amphetamine resinate,
with very few side eﬀects; however, the eﬀectiveness tended
to wear oﬀ after several months of treatment [37].
Side eﬀects, since phentermine is a sympathomimetic
amine, can be expected and include insomnia, dry mouth,
constipation, restlessness, euphoria, nervousness, increased
pulse rate, and blood pressure. The use of noradrenergic
agents is thus not indicated in patients with cardiovascular
disease, hypertension, and history of drug abuse or in those
taking monoamine oxidase inhibitors [21].
3.2.2. Selective Inhibitors of Serotonin Reuptake. Fluoxetine
and sertraline are selective inhibitors of 5-HT reuptake
despite diﬀerent chemical structures. Fluoxetine is a phenyl-
propanolamin oxy-3-fluorphenyl derivate, and sertraline is
a naftilaminic one. They inhibit 5-HT re-uptake at the
presynaptic terminal, and their main indication use is in the
treatment of depression and bulimia. They are not formally
indicated to treat obesity [38], but fluoxetine was used in
adult patients to control hyperphagia, and consequently
obesity correlated with syndromic condition, such as Prader-
Willi syndrome [39].
These agents were found to reduce feeding in experi-
mental animals. In humans, protocol studies, performed to
approve these medications as antidepressants, demonstrated
weight loss in treated subjects. The key problem in managing
these agents is weight regain. Generally, after the first 6
months of treatment, body weight is gradually recovered,
although medication is maintained. Fluoxetine therapy for
obesity management has also been associated with GIT
symptom, sleep disorders, reduced libido, sweating, amnesia,
and thirst [40]. Until now no trials exist about their use to
treat childhood obesity.
3.2.3. Octreotide. Octreotide is a synthetic, eight-amino-
acid analogue of the natural hormone somatostatin. Like
somatostatin, octreotide limits β-cell insulin secretion by
inhibiting the G0 protein associated with the widening
of the voltage-gated calcium channel [41]. It also inhibits
secretion of gastric acid, pancreatic enzymes, and bile,
prolongs intestinal transit time, and decreases gallbladder
contractility. Somatostatin and octreotide inhibit the release
of pituitary and gastro-entero-pancreatic hormones such
as growth hormone (GH), thyroid stimulating hormone
(TSH), glucagon, cholecystokinin (CCK), vasoactive intesti-
nal peptide (VIP), gastrin, and ghrelin [42–44].
Octreotide has been previously shown in both pilot
[45] and placebo-controlled trials [46] to be eﬀective in
reducing insulin secretion, weight, and BMI in children
with hypothalamic obesity. In a pilot study, including obese
adults, suppression of insulin secretion was achieved after a
24-week treatment with octreotide long acting (40mg), and
it was associated with both body weight and fat mass loss
[47].
The most common adverse events were diarrhea,
headache, cholelithiasis, nausea, and abdominal pain [48].
The parenteral administration is one of the major problems
in long-term treatment.
3.2.4. Caﬀeine/Ephedrine. Lipolysis in white and brown
adipocytes is activated by sympathetic stimulation of β-
adrenoreceptors. In rodents, the β3-adrenoceptor plays the
dominant role in these cells. This partly explains why β3-
adrenoceptor agonists are highly eﬀective in causing weight
loss and improving insulin sensitivity in animal models of
obesity and type 2 diabetes. The role of the β3-adrenoceptor
in humans is more controversial. The β3-adrenoceptor
mRNA is expressed in human adipose tissue, but in lower
amounts than in rodents. The receptor is more abundant
in multilocular than in unilocular adipocytes. Its abundance
is lower in adipocytes of obese subjects than lean ones, but
therapy with ephedrine and caﬀeine increased its expression
in obese population.
The ephedrine promotes noradrenaline release as well
as causes some direct stimulation of adrenoreceptors, and
in association with caﬀeine it enhances sympathetic activity.
Indeed, in humans there is evidence that the thermogenic
eﬀect of ephedrine is in part mediated by β3-adrenoceptors
[49] and that the β3-adrenoceptor-mediated component
of this eﬀect is enhanced by repeated administration of
ephedrine or ephedrine plus caﬀeine [50, 51].
Clinical studies demonstrated that obese subjects’
body composition, resting energy expenditure, and lipid
metabolism are overall compatible with a more pronounced
thermogenic and lipolytic eﬀect by ephedrine plus caﬀeine
plus energy restriction as compared to energy restriction
alone [52]. Molna`r et al., in 2000, have published data
about a pilot randomized double-blind placebo-controlled
trial in 32 obese adolescents for 20 weeks, demonstrating
that caﬀeine/ephedrine can be a safe and eﬀective compound
for the treatment of obesity in adolescents, with negligible
adverse events [53].
3.3. New and Future Drugs. Recent advances in the under-
standing of energy balance control have resulted in the
exploitation of a large number of new targets, some of which
have yielded promising data in clinical trials for weight
loss. A second major trend is derived from the hypothesis
that improved weight loss eﬃcacy over current therapy is
more likely to emerge from treatments targeting multiple
mechanisms of energy balance control. Many of these
approaches also utilize advances in formulation technology
to widen safety margins. Finally, the practicality of peptide
therapies for obesity has become better validated in recent
studies, and this may allow more rapid exploitation of
novel targets, rather than awaiting the development of orally
available small molecules [20]. Despite the limitations of
current drugs and their declining use in some jurisdiction,
anti-obesity drugs still accounted for sales of nearly a half-
billion US dollars in the seven largest global markets during
2000 [54, 55]. Since overall sales of anti-obesity drugs
projected to at least triple by 2010 [56], development of
eﬀective drugs has become a research priority and an area
of intense clinical interest.
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The new anti-obesity drugs under clinical development
include agents aﬀecting peripheral and central mechanisms.
In the first group, we can include gastrointestinal lipase
inhibitor (cetilistat), amylin and leptin analogs, thermogenic
agents, that is, selective β3 receptor agonists, agonist of the
glucagon-like peptide 1 (GLP-1) (Exendin-4, Liraglutide).
In the second group, we can consider agents that modulate
the central activity of neuropeptides influencing food intake
and including antiepilepsy drugs (topiramate, zonisamide),
noradrenaline and dopamine reuptake inhibitors (bupro-
pion, tesofensine) that were studied in monotherapy or
in combination (bupropion-naltrexone and phentermine-
topiramate); human ciliary neurotrophic factor (axokine),
human GH fragment (AOD9604, AOD9401), melanocortin
receptor selective agonists (MC4R), melanin-concentrating
hormone antagonists, serotoninergic drugs including selec-
tive 5-HT2C receptor agonists (lorcaserin), components of
neuropeptide Y (NPY) signaling pathway (CAMKK2).
We briefly cite these new drugs, although there are not
yet studies in pediatric population, because these promising,
more eﬃcacious, and better-tolerated treatments for obesity
may become available in the coming future also in pediatric
population.
3.3.1. Drugs Aﬀecting Peripheral Mechanisms
Cetilistat. Cetilistat (ATL-962) is a novel gastrointestinal
lipase inhibitor. A phase II, multicentre, randomized,
placebo-controlled, parallel group study demonstrated that
treatment with cetilistat reduced mean body weight to
similar extents at all doses, which were statistically significant
compared with placebo. Adverse events were generally mild
to moderate in intensity, occurred only on one occasion and
mostly GIT in nature (such as flatus with discharge and oily
spotting). Other lipase inhibitors are under investigation for
obesity treatment [57].
Pramlintide. Pramlintide (Pro25, Pro28, Pro29-amylin), a
soluble synthetic analogue of amylin, is approved in US as
an adjunct to insulin for subcutaneous use in patients with
type 1 or type 2 diabetes who are not able to achieve glucose
control through optimal insulin therapy. Despite the well-
known association between insulin and weight gain, insulin-
treated type 1 or type 2 diabetic patients receiving adjunctive
treatment with pramlintide demonstrated lower hemoglobin
glycosylated levels as well as a significant and sustained
reduction in body weight and BMI [4]. Pramlintide seems to
mediate its anorectic eﬀects (at least in part) through delayed
GIT motility.
Recently, an association with metreleptin showed inter-
esting results [58]. In fact, metreleptin, a leptin agonist, leads
to weight loss that resulted significantly greater if associated
with pramlintide. The greater reduction in body weight was
significant as early as week 4, and weight loss continued
throughout the study, without evidence of a plateau.
The most common adverse eﬀects with pramlin-
tide/metreleptin were injection site events and nausea, which
were mostly mild to moderate and decreased over time.
Beta3-Adrenoceptor Agonists. β3-adrenoceptor is the pre-
dominant subtype of adrenoceptor expressed in adipose
tissue. It mediates the major eﬀects of adrenaline and
noradrenaline in adipose tissues, such as lipolysis in white
adipose tissue and thermogenesis in brown adipose tissue.
β3-adrenoceptor agonist CL.316243 increases fat oxidation
and decreases carbohydrate oxidation in humans [59]. Many
pharmaceutical companies have attempted to develop β3-
adrenoceptor agonists for the treatment of human obesity,
but there is no report on a compound that has progressed
beyond phase II clinical trials [60]. Even though many com-
panies have lost interest in the potential of β3-adrenoceptor
agonists for the treatment of obesity and diabetes, they can
oﬀer useful perspectives on pharmacology, physiology, and
obesity drug discovery [4, 60].
Exendin-4, Liraglutide. The combination of anorectic and
incretin eﬀects of GLP-1 and analogues has attracted much
attention as potential treatment for type 2 diabetes.
Exendin-4 (exenatide) is a natural agonist of the GLP-1
receptor isolated from the lizard Heloderma suspectum and
has longer biological activity than GLP-1. It was recently
approved for the treatment of type 2 diabetes. Twice daily
subcutaneous administration of exenatide in patients with
type 2 diabetes led to a dose-dependent weight loss of 1.8
± 0.3 kg over 28 days, 2.8 ± 0.5 kg over 30 weeks, and 4.7 ±
0.3 kg over 2 years [61].
Liraglutide is a GLP-1 analogue with 97% primary amino
acid homology to native GLP-1, recently approved in Europe
and under evaluation by the FDA in the US. Like exenatide,
liraglutide has been associated with dose-dependent weight
loss in addition to metabolic and cardiovascular benefits:
hemoglobin glycosylated decrease, improvements in triglyc-
eride levels, a mean reduction in systolic and diastolic blood
pressure [62].
Although actual interest in GLP-1 agonists has focused
on their incretin eﬀects for the development of therapeutics
treatment of diabetes [63, 64], it seems likely that obesity
indications will also be reached in the near future, although
these might be limited to obese diabetic patient populations
[4].
3.4. Drugs Aﬀecting Central Mechanisms
3.4.1. Topiramate, Zonisamide, Bupropion, and Tesofensine.
Two antiepileptic drugs (topiramate and zonisamide) and
the antidepressant bupropion have been studied for their
weight loss eﬀects.
The mechanisms by which antiepileptic drugs produce
weight loss are unclear, but they may be due to the antago-
nism of the glutamate kinase receptor by topiramate and to
the serotonergic and dopaminergic activities of zonisamide
[65]. Topiramate therapy was demonstrated to bring on a
high frequency of adverse events due to the central and
peripheral nervous system, such as paresthesias, somnolence,
and diﬃculty with memory; for this reason, trials have been
stopped in phase III while the manufacturers were going
to develop an extended release formulation. Zonisamide’s
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adverse events occurring in the treatment group were fatigue
and a small but significant increase in serum creatinine [65].
In an 8-week-study of weight loss in overweight and
obese women, bupropion, currently marketed for treatment
of depression and as a smoking cessation aid, produced a
6.2% loss of body weight compared with 1.6% weight loss
in the placebo group [65, 66]. Clinicians must be aware of
the 0.4% risk of seizure when the drug dose is 400mg/day.
The mechanism through which the drug leads to weight
loss may be the inhibition of nor-epinephrine and dopamine
uptake [65]. The pooled random-eﬀects estimate of weight
loss in bupropion-treated patients compared with placebo
recipients was 2.77 kg (95% CI, 1.1 to 4.5 kg) [66], and
the same authors indicate that the total weight loss in the
bupropion-treated patients was 4.44 kg. In the adverse events
analysis, there was an increase in dry mouth (pooled odds
ratio:3.26 ; relative risk: 2.99) and no significant increases
in diarrhea and constipation. In addition to dry mouth,
insomnia is a commonly reported side eﬀect in these studies
[66].
Tesofensine is a new drug producing weight loss in
obese individuals. It inhibits the presynaptic re-uptake of
the neurotransmitters noradrenaline, dopamine, and sero-
tonin. In phase II clinical trials with tesofensine in obese
individuals, dose-related reductions in body weight, body fat,
and waist circumference, as well as improvements in other
obesity-related endocrine factors, were observed, while it
was associated with minor adverse events, such as elevations
in heart rate and blood pressure at the highest dose tested
[67].
There are no recent data available on the use of these
drugs in pediatric populations.
3.4.2. Bupropion-Naltrexone (Contrave). Contrave is an oral,
sustained release combination of the dopamine and nor-
epinephrine re-uptake antagonist bupropion and the opioid
antagonist naltrexone. The mechanism of action of the
compound involves complementary stimulation of central
melanocortin pathways, resulting in increased energy expen-
diture and reduced appetite. Preliminary data of phase III
clinical trials in adults demonstrated placebo-subtracted
weight loss of 3 to 7% and improvements in obesity-related
comorbidities and cardiovascular risk factors [68, 69].
3.4.3. Phentermine-Topiramate. We have cited before the
specific characteristic of phentermine and topiramate, but
phentermine HCI/topiramate controlled-release (PHEN/
TPM CR) is a combination agent containing immediate-
release phentermine and controlled-release topiramate. Clin-
ical trials involving thousands of patients demonstrate
PHEN/TPM CR to be eﬀective in improving the weight and
also the adiposopathy-associated metabolic diseases [70].
3.4.4. Endocannabinoid Receptor Blockers (Rimonabant,
Taranabant). Endocannabinoid (ECB) receptor blockers,
such as rimonabant, were initially intended as an anti-
obesity and smoking cessation dual-purpose drug; however,
the latter development program has been discontinued [20,
71]. ECB produces a dose-dependent reduction in food
intake in various rodent models, and these eﬀects seem to
be both centrally and peripherally mediated [72]. Potential
peripheral mechanisms include enhanced thermogenesis
increasing oxygen consumption in skeletal muscle [73],
reducing hepatic [74] and adipocyte lipogenesis [75], aug-
menting adiponectin concentrations [76], promoting vagus-
mediated cholecystokinin-induced satiety [77, 78], inhibit-
ing preadipocyte proliferation, and increasing adipocyte
maturation without lipid accumulation [79].
Rimonabant in the United Kingdom was indicated for
patients whose BMI exceeds 30 kg/m2 or who had associated
factors such as type 2 diabetes and/or dyslipidemia, while
in other countries obesity alone was not an indication for
its use and abnormal blood lipid levels are also required for
the prescription [80]. Recently European Medicines Agency
decided the withdrawal of rimonabant from the European
market because of its important side eﬀects.
Taranabant is a novel cannabinoid CB1 receptor inverse
agonist that is in clinical development for the treatment of
obesity. Mechanism-of-action studies suggest that engage-
ment of the CB1 receptor by taranabant leads to weight loss
by reducing food intake and increasing energy expenditure
and fat oxidation [81]. Recent studies have demonstrated a
weight loss after a 12-week therapy in obese adults, inducing
statistically significant weight loss compared to placebo in
obese subjects over the entire range of evaluated doses (0.5, 2,
4, and 6mg once per day) (P < .001). Taranabant treatment
was associated with dose-related increased incidence of
clinical adverse events, including mild to moderate GIT and
psychiatric eﬀects.
3.4.5. Ciliary Neurotrophic Factor. Ciliary neurotrophic fac-
tor (CNTF) was originally characterized as a trophic factor
supporting the survival of embryonic chick ciliary ganglion
neurons in vitro [82, 83]. Initially, CNTF was described
as being predominantly distributed within neural tissues
[84] but it was also reported in skeletal muscle, adrenal
gland, sciatic nerve, skin, kidney, and testes [85]. Although
CNTF was firstly identified as a trophic factor in the ciliary
ganglion, it was later found to act on other motor neuron
populations [86]. Hence, it was evaluated as a therapeutic
tool in patients suﬀering from motor neuron diseases
[87]. Interestingly, during these trials, CNTF administration
resulted in unexpected weight loss. CNTF can also cross the
blood-brain barrier in a manner similar to leptin [88]. CNTF
and its synthetic analogue, axokine, have also been found to
suppress NPY gene expression [89]. It is believed to occur
by resetting the hypothalamic weight set point, such that
cessation of CNTF treatment does not result in overeating
and rebound weight gain [90]. The results of recent studies
have suggested that CNTF and axokine may play a role in the
regulation of adipocytemetabolism and, perhaps, the control
of adipose tissue mass, supporting the hypothesis that weight
loss due to CNTF is not solely mediated by the CNS [91].
CNTF or axokine [92] failed first phase III trial because
two-thirds of the patients developed antibodies against this
factor. Thus, further studies have to be made to understand
the eﬀectiveness of the drug and its possible side eﬀects.
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3.4.6. Analogue (AOD9604-AOD9401) of Human Growth
Hormone. It has generally been recognized that human GH
(hGH) exerts a profound eﬀect on body composition and
systemic hGH administration reduces body fat mass as
well as fat distribution. The use of hGH for the treatment
of human obesity has not been advocated due to serious
side eﬀects, including glucose intolerance, insulin resistance,
sodium retention, hypertension, edema, and carpal tunnel
syndrome [93].
The aminoterminus of the hGH molecule is the func-
tional domain for the insulin-like action of the hormone.
Some studies have identified the specific metabolic domain
responsible for the lipolytic/antilipogenic activity of the
hGH molecule, referred as AOD9604 and studied for its
metabolic actions in obese rats. Daily treatment with an
oral dose of AOD9604 (500 μg/kg) for 19 days reduced over
50% of body weight gain of the animals in comparison
with the control. The adipose tissues of the AOD9604-
treated animals were found to present an increase in lipolytic
activity. In contrast to chronic treatment with intact hGH,
the chronic treatment with AOD9604 showed no adverse
eﬀect on insulin sensitivity, as demonstrated with euglycemic
clamp techniques [94]. Unfortunately, AOD9604 recently
failed phase IIb trials for obesity.
Another lipolytic domain (referred as AOD9401) of
hGH, has been synthesized using solid-phase peptide synthe-
sis techniques. This analogue of the hGH lipolytic domain
may have the potential to be developed into an orally usable
and safe therapeutic agent for obesity. Up to now, no human
studies have been yet performed [94].
3.4.7. Melanocortin Receptor Selective (MC4R) Agonists.
Much eﬀort is currently underway to develop melanocortin
receptor selective compounds directed for clinical use, with a
focus on the development of MC4R selective agonists to treat
obesity. There is, on the other hand, the possibility of treating
anorectic and cachectic conditions with MC4R antagonists
[95].
The most reported side eﬀects of this drug appear to be
mild and include flushing, somnolence, nausea, vomiting,
headache, and taste disturbances [54, 96]. The only available
clinical trial data on the eﬀect of an MC4R agonist was
conducted with adrenocorticotropic hormone (an agonist
of MC4R) to assess its potential to cause weight reduction
in humans. Therefore, clinical trials with proper drug
candidates are needed.
3.4.8. Melanin-Concentrating Hormone (MCH) Antagonists.
MCHR1 antagonists (recently patented) [97, 98] are one
class of agents that shows particularly good promise for
treating obesity that has now been well validated in animal
models but remains to be validated in human clinical trials.
MCHR1 antagonists reduce food intake, particularly highly
palatable food, and subsequently decreases body weight,
primarily due to decreased fat mass. Depending upon the
animal model and paradigm utilized in the studies, MCHR1
antagonists also were shown to increase energy expenditure
resulting in weight loss. Together, these data suggest that
MCHR1 antagonists may be a key component in a program
of diet, exercise, and therapeutic intervention in reducing the
energy “gap” to allow people better regulation of their weight.
A number of significant safety, selectivity, and metabolic sta-
bility hurdles were presented that continue to be challenges
for pharmaceutical companies in their eﬀort/research to be
the first to deliver a new therapeutic agent targeting this
receptor. Since, to date, only three companies have initiated
clinical trials, and only one has reported conclusion of a
first-in-human trial there is still a long road and many
years ahead before a compound targeting MCHR1 receptors
could ultimately be marketed for the treatment of obesity
[98].
3.4.9. Serotonergic Drugs. M-chlorophenylpiperazine (mCPP)
is a 5-HT2C receptor agonist studied in insulin resistant
mouse models showing beneficial eﬀects on glucose home-
ostasis and weight gain [40]. Diet-induced obese mice and
leptin-deficient (ob/ob) mice treated for 2 weeks exhibited
a dramatic 50% reduction in plasma insulin levels in both
models. This was without eﬀects on blood glucose, food
intake, activity, or body mass at the doses used in this study.
Pharmacological blockage of 5-HT2C receptors abolished
eﬀects on glucose tolerance, verifying that these eﬀects were
directly mediated by 5-HT2C receptors [97]. mCPP has been
shown to modify appetite in both lean and obese humans.
A new generation of 5-HT2C receptor agonist is devel-
oping [97]. Recent studies show APD-356 (lorcaserin) to be
a potent, selective, and eﬃcacious agonist of the 5-HTC2
receptor, with potential for the treatment of obesity [99].
3.4.10. Ca2+/Calmodulin-Dependent Protein Kinase Kinase
2 (CaMKK2). Recently, the adenosine monophosphate-
dependent protein kinase (AMPK) was identified as one
component of NPY signaling pathway. Acute intracere-
broventricular (icv) administration of a CaMKK2 null
mice resulted in decreased food intake that was correlated
with decreased hypothalamic NPY and AgRP mRNAs. The
absence of CaMKK2 was also demonstrated to protect
mice from diet-induced weight gain, hyperglycemia, and
insulin resistance. Furthermore, icv infusion of the selective
CaMKK2 inhibitor STO-609 in adult WT mice resulted in
the acute suppression of NPY expression and food intake.
The resistance of CaMKK2 null mice to suppression of food
intake by STO-609 infusion provides compelling evidence
that CaMKK2 is the direct target of the drug and that the
specific inhibition of CaMKK2 in NPY neurons is likely
responsible for the reduced level of NPY and AgRP mRNAs
and feeding behavior [100].
Thus, the behavior of CaMKK2 null mice on the high-fat
diet underscores the value of targeting CaMKK2 as a possible
therapeutic locus in the treatment of obesity and diabetes
[100].
4. Conclusions
Childhood obesity is not only a cosmetic problem. Many
adverse health eﬀects associated with adult obesity are
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already being seen in obese adolescents in which a significant
increase in the cardiovascular risk has been observed,
probably due to obesity-metabolic disarrangement (most
incidence of hypertension, type 2 diabetes, and dyslipi-
demia), but also other co-morbidities such as nonalcoholic
fatty liver disease, idiopathic intracranial hypertension, sleep
apnea, and orthopedic abnormalities. In summary, there
is insuﬃcient evidence to conclude that any one-treatment
approaches is superior in the management of adolescent
obesity. However, the use of psychological interventions
such us behavioral therapy and cognitive behavioral therapy,
combined with strategies to improve diet and physical
activity, shows promise.
The neurobiology of obesity is extremely complex with
many overlapping and redundant pathways. This complexity
decreases the probability that targeting any single pathway
will result in dramatic weight loss and suggests that multiple
drugs with diﬀerent mechanisms will be needed to determine
significant and persistent weight loss [20]. Although newer
drugs are years away from clinical use, the hope for research
investments made to date is translation into safe and eﬀective
anti-obesity drugs in the future. The search for novel drug
treatments for obesity in childhood and adolescents is,
therefore, both legitimate and necessary.
However, in our eﬀorts to fill the therapeutic void
that characterizes contemporary obesity management, the
benefits of obesity pharmacotherapy must outweigh the risks
and costs.
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